CAPLIN POINT LABORATORIES LTD.

Caplin Point Laboratories Ltd has informed the stock exchanges about the dispatch of the Notice for its 35th Annual General Meeting (AGM) and the Annual Report for the financial year 2025-26. This communication is being sent to shareholders who have not registered their email addresses, providing a weblink to access these documents. The AGM is scheduled to be held on September 25, 2026, via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company encourages shareholders to update their email addresses for future communications.

Caplin Point Laboratories Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as per SEBI regulations. The report covers the company and its subsidiaries, Caplin Steriles Limited and Caplin One Labs Limited, focusing on manufacturing and sale of pharmaceuticals, which accounts for 100% of its turnover. The company has obtained limited assurance on its BRSR Core disclosures from M/s Alagar & Associates LLP. The report details corporate identity, operational locations, and business activities.

Caplin Point Laboratories Ltd has announced its 35th Annual General Meeting (AGM) will be held on Friday, September 25, 2026, at 10:00 AM IST via Video Conferencing/Other Audio Visual Means. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY26, declaration of a final dividend of ₹4 per share, and ratification of an interim dividend of ₹4 per share, totaling ₹8 per share. The AGM will also address the re-appointment of Dr. Sridhar Ganesan, who retires by rotation, and his re-appointment as Managing Director for a two-year term with a remuneration package including an annual salary of ₹55,20,000.

Caplin Point Laboratories Ltd announced its Annual Report for FY26, highlighting robust financial performance. Revenue grew 12.89% to ₹2,187 Crores, with net profit surging 20.08% to ₹650 Crores. The company emphasized a decade-long pattern of profit compounding at approximately 27% without debt funding. Key developments include Caplin Steriles USA achieving profitability in its first year, backward integration, and expansion plans in Mexico and Guatemala. Free cash reserves stand at ₹1,471 Crores, showing 21X growth over the decade. The 35th Annual General Meeting is scheduled for September 25, 2026.

Caplin Point Laboratories Ltd announced that its subsidiary, Caplin Steriles Limited, has completed an unannounced inspection by the United States Food and Drug Administration (US FDA) at its injectable and ophthalmic manufacturing facility in Gummidipoondi. The inspection, conducted from August 13 to August 21, 2026, resulted in the company receiving Form 483 with 10 observations. Caplin Point stated that these observations are procedural and do not pertain to data integrity, nor were they repeat observations. The company is actively addressing these points and will submit its response to the US FDA within the stipulated timeframe.

Caplin Point Laboratories Ltd announced board approval for the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years from August 25, 2026, and the appointment of Mr. D. Muralidharan as Whole-Time Director for two years from August 12, 2026. Mr. Muralidharan will continue as CFO. Both appointments are subject to shareholder approval. Dr. Ganesan brings over 35 years of pharmaceutical leadership experience, while Mr. Muralidharan is a seasoned finance professional with extensive experience as CFO since 2016.

Caplin Point Laboratories Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors also recommended a Final Dividend of ₹4/- (200%) per equity share for the financial year ended March 31, 2026. Additionally, the company approved the re-appointment of Dr. Sridhar Ganesan as Managing Director and the appointment of Mr. D. Muralidharan as Whole-Time Director. The 35th Annual General Meeting is scheduled for September 25, 2026.

Caplin Point Laboratories Ltd has announced September 18, 2026, as the record date for its final dividend for the financial year 2025-26. This decision was made in conjunction with the approval to convene the 35th Annual General Meeting (AGM) on September 25, 2026. The dividend payment is contingent on its declaration at the upcoming AGM. The company has also set the record date for the AGM itself, aligning with the dividend record date.

Caplin Point's consolidated Q1 FY27 revenue from operations came in at ₹610.4 Cr, up 19.6% YoY (₹510.2 Cr) and 1.7% QoQ; total revenue (including other income) was ₹643.9 Cr, +20.7% YoY. Consolidated PAT (net profit for the period, before minority interest) was ₹179.1 Cr, up 18.8% YoY and 3.6% QoQ, with basic EPS of ₹23.27 versus ₹20.10 a year ago. Neither the current nor the year-ago quarter carries any exceptional item, so this is a clean, comparable growth number. Management issued no formal quantitative guidance ahead of this print, so there is no company target to grade against; the closest available yardstick is broad analyst consensus (not quarter-specific) pegging FY27 PAT growth at 15-20% — the 18.8% YoY print sits within that band. The operating story was actually stronger than the PAT growth alone suggests: EBITDA rose 23.0% YoY to ₹247.0 Cr with the EBITDA margin expanding to 38.4% from 37.7%, and PBT/EBIT margin rose to 35.0% from 34.6%. But gross margin slipped to 59.8% from 61.7% YoY as purchased/traded goods took a larger share of the cost mix, and the effective tax rate jumped to 20.5% (₹46.1 Cr tax on ₹225.2 Cr PBT) from 18.3% a year ago, compounded by a 32.8% YoY rise in depreciation as new capacity comes online. Net effect: consolidated PAT margin actually compressed to 27.8% from 28.3% YoY even as operating profitability improved — the quarter's real story is healthy operating leverage being partly offset below the line by tax and D&A, not a demand or pricing issue. US revenue was the standout at ₹137 Cr (per the press release), +26% YoY, now roughly 22% of the geographic mix versus 78% for Emerging Markets; by segment, Rest-of-World PBT grew to ₹158.4 Cr (Q1FY26: ₹151.5 Cr) while the USA segment's PBT nearly tripled YoY to ₹33.3 Cr (from ₹9.9 Cr) — the regulated-market business is scaling faster than its still-smaller revenue base, backed by Caplin Steriles' 60 approved ANDAs (40+ more filing/in development) and CSU's own-label US business (33 launches to date, ~90% market-share retention on launched products). Alongside results, the board recommended a ₹4/share (200%) final dividend on top of the ₹4 interim already paid in June, taking total FY26 dividend to ₹8/share, and approved Dr. Sridhar Ganesan's MD reappointment (two more years from Aug 25, 2026) plus D. Muralidharan's elevation to Whole-Time Director while he retains the CFO role. Chairman C.C. Paarthipan's press-release commentary framed the quarter as delivering "healthy growth across both Emerging Markets and the US" with "disciplined execution" — the revenue and EBITDA numbers support that framing, though management's commentary does not address the tax-rate increase that capped net profit growth. Free cash reserves stood at ₹1,502 Cr and total liquid assets at ₹2,875 Cr as of June 30, 2026, funding a ~₹1,000+ Cr capex program (roughly half nearing completion) entirely from internal accruals — the Pondicherry OSD/Dermatology expansion and the Gummidipoondi COL injectable facility are both targeted for Q1 FY28, and the Thervoy oncology API facility for Q4 FY27. With no formal guidance on record, the checkpoints going into Q2 are whether the effective tax rate normalizes, whether gross margin recovers off the traded-goods mix shift, and whether the 12 planned US launches and the first Pre-Filled Syringe filing materialize within FY27 as management indicated.

Caplin Point Laboratories Ltd has announced a Board of Directors meeting scheduled for August 12, 2026. The primary agenda items include the consideration and approval of the unaudited financial results for the first quarter ended June 30, 2026 (standalone and consolidated). Additionally, the board will discuss the recommendation of a final dividend for the fiscal year 2025-26, the convening of the 35th Annual General Meeting, and the fixation of a record date for dividend eligibility. The company also reiterated its trading window closure for designated persons from July 1, 2026, to August 14, 2026.